What to look out for at the ESMO cancer meeting
This article was originally published in Scrip
Immuno-oncology is set to keep its place in the forefront of oncology R&D at the European Society for Medical Oncology (ESMO) meeting in Madrid from 26-30 September.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.